Stachydrine promotes angiogenesis by regulating the VEGFR2/MEK/ERK and mitochondrial-mediated apoptosis signaling pathways in human umbilical vein endothelial cells - 28/10/20
páginas | 9 |
Iconografías | 8 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | Stachydrine promoted proliferation, migration, and tube formation in HUVECs. |
• | Stachydrine upregulated the VEGFR2/MEK/ERK pathway to promote angiogenesis. |
• | Stachydrine suppressed the mitochondrial-mediated apoptosis pathway to promote angiogenesis. |
Abstract |
Stachydrine is a main active component of Leonurus japonicus (Chinese motherwort), which has traditionally been used to promote postpartum recovery and alleviate myocardial and cerebral ischemic injuries due to its pro-angiogenic effect. Our prior study demonstrated that stachydrine increased angiogenesis in zebrafish embryos, but its pro-angiogenic effect and underlying mechanisms on human umbilical vein endothelial cells (HUVECs) remain largely unknown. In the present study, we further investigated the role of stachydrine in sunitinib-injured HUVECs and its potential molecular mechanisms. The results showed that stachydrine exhibited a protective effect on sunitinib-injured HUVECs and significantly promoted their proliferation, migration, and tube formation, all central events of angiogenesis. In addition, stachydrine inhibited apoptosis and ROS production in sunitinib-injured HUVECs. Furthermore, our findings illustrated for the first time that stachydrine’s molecular mechanisms for promoting angiogenesis might correlate with activation of the VEGFR2/MEK/ERK and inhibition of the mitochondrial-mediated apoptosis signaling pathway.
El texto completo de este artículo está disponible en PDF.Keywords : Leonurus japonicus, Stachydrine, HUVECs, Angiogenesis, VEGFR2/MEK/ERK pathway, Mitochondrial-mediated apoptosis pathway
Esquema
Vol 131
Artículo 110724- novembre 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?